These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10819372)

  • 21. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level.
    Martínez-Arribas F; Alvarez T; Del Val G; Martín-Garabato E; Núñez-Villar MJ; Lucas R; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2007; 27(1A):219-22. PubMed ID: 17352236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma.
    Coppola D; Fu L; Nicosia SV; Kounelis S; Jones M
    Hum Pathol; 1998 May; 29(5):455-62. PubMed ID: 9596268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis.
    Masuda M; Takano Y; Iki M; Asakura T; Hashiba T; Noguchi S; Hosaka M
    Pathol Int; 1998 Jan; 48(1):41-6. PubMed ID: 9589463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma.
    Bhatavdekar JM; Patel DD; Ghosh N; Chikhlikar PR; Trivedi TI; Suthar TP; Doctor SS; Shah NG; Balar DB
    Dis Colon Rectum; 1997 Jul; 40(7):785-90. PubMed ID: 9221853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of E-cadherin and bcl-2 on prognosis in patients with breast cancer.
    Kavgaci H; Yildiz B; Fidan E; Reis A; Ozdemir F; Cobanoglu U; Can G
    Bratisl Lek Listy; 2010; 111(9):493-7. PubMed ID: 21180263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors.
    Moazzezy N; Ebrahimi F; Sisakht MM; Yahyazadeh H; Bouzari S; Oloomi M
    Asian Pac J Cancer Prev; 2016; 17(1):249-54. PubMed ID: 26838218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma.
    Giatromanolaki A; Stathopoulos GP; Tsiompanou E; Papadimitriou C; Georgoulias V; Gatter KC; Harris AL; Koukourakis MI
    Cancer; 1999 Oct; 86(8):1421-30. PubMed ID: 10526268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 and related proteins in epithelial ovarian cancer.
    Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
    Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2].
    Han PH; Li XJ; Qin H; Yao J; DU N; Ren H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Aug; 25(8):710-3. PubMed ID: 19664395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. bcl-2 and apoptosis in lymph node positive breast carcinoma.
    Berardo MD; Elledge RM; de Moor C; Clark GM; Osborne CK; Allred DC
    Cancer; 1998 Apr; 82(7):1296-302. PubMed ID: 9529021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
    Skírnisdóttir I; Seidal T
    Oncol Rep; 2012 Mar; 27(3):741-7. PubMed ID: 22159712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
    Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
    Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
    Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
    J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
    Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
    Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.